Armata receives $4.65M additional DoD funding for phage therapy trial; topline data Q2 2025

Armata Pharmaceuticals, Inc.

Received $4.65M additional non-dilutive DoD funding for AP-SA02; total award now $26.2M.
Phase 1b/2a diSArm trial of AP-SA02 for S. aureus bacteremia enrolled 50 subjects; last visit Jan 2025.
Two subsets observed: one with in vivo phage amplification suggesting phage activity despite antibiotics.
Topline data expected in Q2 2025 to inform optimal dose for larger efficacy trial.
Going concern note in 2024 10-K remains unchanged per company disclosure.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.